Form 6-K NERVGEN PHARMA CORP. For: Jun 01

Mon, 01 Jun 2026 17:29:00 -0400

si-local-file:///var/storage/secattach/20260601/26585204.html

Form 6-K NERVGEN PHARMA CORP. For: Jun 01

Mon, 01 Jun 2026 17:29:00 -0400

si-local-file:///var/storage/secattach/20260601/26585204.html

Form EFFECT NERVGEN PHARMA CORP.

Wed, 27 May 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260527/26552941.html

Form EFFECT NERVGEN PHARMA CORP.

Wed, 27 May 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260527/26552941.html

Form 6-K NERVGEN PHARMA CORP. For: May 26

Tue, 26 May 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260526/26550660.html

Form 6-K NERVGEN PHARMA CORP. For: May 26

Tue, 26 May 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260526/26550660.html

Form SUPPL NERVGEN PHARMA CORP.

Tue, 26 May 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260526/26550590.html

Form SUPPL NERVGEN PHARMA CORP.

Tue, 26 May 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260526/26550590.html

Form F-X NERVGEN PHARMA CORP. Filed by: NERVGEN PHARMA CORP.

Tue, 26 May 2026 09:40:00 -0400

si-local-file:///var/storage/secattach/20260526/26547125.html

Form F-X NERVGEN PHARMA CORP. Filed by: NERVGEN PHARMA CORP.

Tue, 26 May 2026 09:40:00 -0400

si-local-file:///var/storage/secattach/20260526/26547125.html

Form F-10 NERVGEN PHARMA CORP.

Tue, 26 May 2026 09:26:00 -0400

si-local-file:///var/storage/secattach/20260526/26547033.html

Form F-10 NERVGEN PHARMA CORP.

Tue, 26 May 2026 09:26:00 -0400

si-local-file:///var/storage/secattach/20260526/26547033.html

NervGen reports positive biomechanical gait analysis data for NVG-291

Tue, 26 May 2026 07:15:17 -0400

NervGen Pharma Corp. (NASDAQ: NGEN) announced results from independent, blinded biomechanical gait analyses of its drug candidate NVG-291 in patients with chronic spinal cord injury. The analyses were conducted as part of the company's Phase 1b/2a CONNECT SCI study.

The biomechanical analyses were performed by Newton Tech using video-based motion capture technology to evaluate gait quality. The study measured coordination, mechanical effort, and postural stability as indicators of neural recovery versus compensatory movement patterns.

According to the company's announcement, NVG-291 demonstrated statistically significant improvement in gait quality compared to placebo (p=0.0197) based on a Global Statistical Test. The analysis showed that all

NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study

Tue, 26 May 2026 07:15:00 -0400

NVG-291 demonstrated statistically significant improvement in gait quality (p=0.0197), based on a Global Statistical Test integrating the established hallmarks of genuine neural recovery into a unified assessment of treatment benefit.
Based on the Global Statistical Test, 100% (10/10) of NVG-291 subjects were classified as responders across the composite of the hallmarks of genuine neural recovery, versus 10% (1/10) of placebo subjects (p=0.0001).
These biomechanical gait findings join reported improvements in electrophysiological signaling, functional hand use, and quality of life, reflecting a consistent, multi-domain pattern of benefit with NVG-291 in the Phase 1b/2a CONNECT SCI study.

NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study

Tue, 26 May 2026 07:15:00 -0400

NVG-291 demonstrated statistically significant improvement in gait quality (p=0.0197), based on a Global Statistical Test integrating the established hallmarks of genuine neural recovery into a unified assessment of treatment benefit.
Based on the Global Statistical Test, 100% (10/10) of NVG-291 subjects were classified as responders across the composite of the hallmarks of genuine neural recovery, versus 10% (1/10) of placebo subjects (p=0.0001).
These biomechanical gait findings join reported improvements in electrophysiological signaling, functional hand use, and quality of life, reflecting a consistent, multi-domain pattern of benefit with NVG-291 in the Phase 1b/2a CONNECT SCI study.

NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study

Tue, 26 May 2026 07:15:00 -0400

NVG-291 demonstrated statistically significant improvement in gait quality (p=0.0197), based on a Global Statistical Test integrating the established hallmarks of genuine neural recovery into a unified assessment of treatment benefit.
Based on the Global Statistical Test, 100% (10/10) of NVG-291 subjects were classified as responders across the composite of the hallmarks of genuine neural recovery, versus 10% (1/10) of placebo subjects (p=0.0001).
These biomechanical gait findings join reported improvements in electrophysiological signaling, functional hand use, and quality of life, reflecting a consistent, multi-domain pattern of benefit with NVG-291 in the Phase 1b/2a CONNECT SCI study.

NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study

Tue, 26 May 2026 07:15:00 -0400

NVG-291 demonstrated statistically significant improvement in gait quality (p=0.0197), based on a Global Statistical Test integrating the established hallmarks of genuine neural recovery into a unified assessment of treatment benefit.
Based on the Global Statistical Test, 100% (10/10) of NVG-291 subjects were classified as responders across the composite of the hallmarks of genuine neural recovery, versus 10% (1/10) of placebo subjects (p=0.0001).
These biomechanical gait findings join reported improvements in electrophysiological signaling, functional hand use, and quality of life, reflecting a consistent, multi-domain pattern of benefit with NVG-291 in the Phase 1b/2a CONNECT SCI study.

Form 6-K NERVGEN PHARMA CORP. For: May 22

Fri, 22 May 2026 17:24:00 -0400
si-local-file:///var/storage/secattach/20260522/26542931.html

Form 6-K NERVGEN PHARMA CORP. For: May 22

Fri, 22 May 2026 17:24:00 -0400
si-local-file:///var/storage/secattach/20260522/26542931.html

Form SUPPL NERVGEN PHARMA CORP.

Fri, 22 May 2026 17:20:00 -0400
si-local-file:///var/storage/secattach/20260522/26542897.html

Form SUPPL NERVGEN PHARMA CORP.

Fri, 22 May 2026 17:20:00 -0400
si-local-file:///var/storage/secattach/20260522/26542897.html

NervGen prices $60 million public offering at $2.50 per share

Thu, 21 May 2026 23:27:14 -0400

NervGen Pharma Corp. (NASDAQ: NGEN) announced the pricing of an underwritten public offering of 24 million common shares and accompanying warrants at $2.50 per share. The clinical-stage biopharmaceutical company expects gross proceeds of approximately $60 million before deducting underwriting costs and expenses.

Each share includes a warrant to purchase one additional common share at an exercise price of $3.68. The warrants are immediately exercisable upon issuance and expire five years from the issuance date. The offering is scheduled to close on May 26, 2026, subject to customary closing conditions.

The securities will be offered in all Canadian provinces and territories except Quebec.

NervGen Announces Pricing of US$60.0 Million Public Offering of Securities

Thu, 21 May 2026 23:27:00 -0400

VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other neurotraumatic and neurologic conditions, today announced the pricing of an underwritten public offering of 24,000,000 common shares and accompanying warrants to purchase up to 24,000,000 common shares. The common shares are being sold at a public offering price of US$2.50 per common share and accompanying warrant. Each accompanying warrant has an exercise price of US$3.68 per common share, and will be immediately exercisable from the date

NervGen Announces Pricing of US$60.0 Million Public Offering of Securities

Thu, 21 May 2026 23:27:00 -0400

VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other neurotraumatic and neurologic conditions, today announced the pricing of an underwritten public offering of 24,000,000 common shares and accompanying warrants to purchase up to 24,000,000 common shares. The common shares are being sold at a public offering price of US$2.50 per common share and accompanying warrant. Each accompanying warrant has an exercise price of US$3.68 per common share, and will be immediately exercisable from the date

NervGen Announces Pricing of US$60.0 Million Public Offering of Securities

Thu, 21 May 2026 23:27:00 -0400

VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other neurotraumatic and neurologic conditions, today announced the pricing of an underwritten public offering of 24,000,000 common shares and accompanying warrants to purchase up to 24,000,000 common shares. The common shares are being sold at a public offering price of US$2.50 per common share and accompanying warrant. Each accompanying warrant has an exercise price of US$3.68 per common share, and will be immediately exercisable from the date

StreetInsider.com News Articles

Form 6-K NERVGEN PHARMA CORP. For: Jun 01

Form 6-K NERVGEN PHARMA CORP. For: Jun 01

Form EFFECT NERVGEN PHARMA CORP.

Form EFFECT NERVGEN PHARMA CORP.

Form 6-K NERVGEN PHARMA CORP. For: May 26

Form 6-K NERVGEN PHARMA CORP. For: May 26

Form SUPPL NERVGEN PHARMA CORP.

Form SUPPL NERVGEN PHARMA CORP.

Form F-X NERVGEN PHARMA CORP. Filed by: NERVGEN PHARMA CORP.

Form F-X NERVGEN PHARMA CORP. Filed by: NERVGEN PHARMA CORP.

Form F-10 NERVGEN PHARMA CORP.

Form F-10 NERVGEN PHARMA CORP.

NervGen reports positive biomechanical gait analysis data for NVG-291

NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study

NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study

NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study

NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study

Form 6-K NERVGEN PHARMA CORP. For: May 22

Form 6-K NERVGEN PHARMA CORP. For: May 22

Form SUPPL NERVGEN PHARMA CORP.

Form SUPPL NERVGEN PHARMA CORP.

NervGen prices $60 million public offering at $2.50 per share

NervGen Announces Pricing of US$60.0 Million Public Offering of Securities

NervGen Announces Pricing of US$60.0 Million Public Offering of Securities

NervGen Announces Pricing of US$60.0 Million Public Offering of Securities